1. Assessment of Maraviroc Exposure–Response Relationship at 48 Weeks in Treatment‐Experienced HIV‐1–Infected Patients in the MOTIVATE Studies. (14th August 2013) Authors: Jacqmin, P; Wade, JR; Weatherley, B; Snoeck, E; Marshall, S; McFadyen, L Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 2:Number 8(2013:Aug.) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens. (July 2021) Authors: Lewis, ME; Simpson, P; Mori, J; Jubb, B; Sullivan, J; McFadyen, L; van der Ryst, E; Craig, C; Robertson, DL; Westby, M Journal: Antiviral chemistry & chemotherapy Issue: Volume 29(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗